{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:40:54Z","timestamp":1791726054320,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01-AI145435-A1"],"award-info":[{"award-number":["R01-AI145435-A1"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01-AI153349"],"award-info":[{"award-number":["R01-AI153349"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21- AI149760"],"award-info":[{"award-number":["R21- AI149760"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K08-AI139371"],"award-info":[{"award-number":["K08-AI139371"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01-HL131829"],"award-info":[{"award-number":["R01-HL131829"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-50989-4","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T06:03:10Z","timestamp":1723615390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1574-7759","authenticated-orcid":false,"given":"Xueyi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavatharini","family":"Arun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar J.","family":"Nino-Meza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona O.","family":"Sarhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3993-6486","authenticated-orcid":false,"given":"Byeonghoon","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishor","family":"Mane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maunank","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth W.","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence S.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-3455","authenticated-orcid":false,"given":"Joel S.","family":"Freundlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9002-7052","authenticated-orcid":false,"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6433-1154","authenticated-orcid":false,"given":"Vijay D.","family":"Ivaturi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9620-7070","authenticated-orcid":false,"given":"Sanjay K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"50989_CR1","first-page":"445","volume":"2","author":"P Ehrlich","year":"1913","unstructured":"Ehrlich, P. Chemotherapeutics: scientific principles, methods, and results. Address in pathology to 17th International Congress of Medicine (London, 1913). Lancet 2, 445\u2013451 (1913).","journal-title":"Lancet"},{"key":"50989_CR2","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1128\/AAC.48.5.1441-1453.2004","volume":"48","author":"M Muller","year":"2004","unstructured":"Muller, M., dela Pena, A. & Derendorf, H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob. Agents Chemother. 48, 1441\u20131453 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"50989_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41590-018-0119-x","volume":"19","author":"SK Jain","year":"2018","unstructured":"Jain, S. K. et al. Tuberculous meningitis: a roadmap for advancing basic and translational research. Nat. Immunol. 19, 521\u2013525 (2018).","journal-title":"Nat. Immunol."},{"key":"50989_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrneurol.2017.120","volume":"13","author":"RJ Wilkinson","year":"2017","unstructured":"Wilkinson, R. J. et al. Tuberculous meningitis. Nat. Rev. Neurol. 13, 581\u2013598 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"50989_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1474-4422(21)00435-X","volume":"21","author":"J Huynh","year":"2022","unstructured":"Huynh, J. et al. Tuberculous meningitis: progress and remaining questions. Lancet Neurol. 21, 450\u2013464 (2022).","journal-title":"Lancet Neurol."},{"key":"50989_CR6","doi-asserted-by":"publisher","first-page":"e145107","DOI":"10.1172\/JCI145107","volume":"131","author":"AA Ordonez","year":"2021","unstructured":"Ordonez, A. A. et al. Visualizing the dynamics of Tuberculosis pathology using molecular imaging. J. Clin. Invest. 131, e145107 (2021).","journal-title":"J. Clin. Invest."},{"key":"50989_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35730-3","volume":"13","author":"F Mota","year":"2022","unstructured":"Mota, F. et al. Dynamic (18)F-Pretomanid PET imaging in animal models of TB meningitis and human studies. Nat. Commun. 13, 7974 (2022).","journal-title":"Nat. Commun."},{"key":"50989_CR8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41591-020-0770-2","volume":"26","author":"AA Ordonez","year":"2020","unstructured":"Ordonez, A. A. et al. Dynamic imaging in patients with Tuberculosis reveals heterogeneous drug exposures in pulmonary lesions. Nat. Med. 26, 529\u2013534 (2020).","journal-title":"Nat. Med."},{"key":"50989_CR9","unstructured":"Johns Hopkins University. Biodistribution and Pharmacokinetics of Pretomanid in Tuberculosis Patients Using 18F-Pretomanid PET. (ClinicalTrials.gov, 2024)."},{"key":"50989_CR10","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s40265-019-01207-9","volume":"79","author":"SJ Keam","year":"2019","unstructured":"Keam, S. J. Pretomanid: First approval. Drugs 79, 1797\u20131803 (2019).","journal-title":"Drugs"},{"key":"50989_CR11","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1093\/infdis\/jit331","volume":"208","author":"CA Foss","year":"2013","unstructured":"Foss, C. A., Harper, J. S., Wang, H., Pomper, M. G. & Jain, S. K. Noninvasive molecular imaging of Tuberculosis-associated inflammation with radioiodinated DPA-713. J. Infect. Dis. 208, 2067\u20132074 (2013).","journal-title":"J. Infect. Dis."},{"key":"50989_CR12","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2967\/jnumed.117.207431","volume":"59","author":"CA Foss","year":"2018","unstructured":"Foss, C. A. et al. Biodistribution and radiation dosimetry of (124)I-iodo-DPA-713, a PET radiotracer for macrophage-associated inflammation. J. Nucl. Med. 59, 1751\u20131756 (2018).","journal-title":"J. Nucl. Med."},{"key":"50989_CR13","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1128\/AAC.04180-14","volume":"59","author":"AA Ordonez","year":"2015","unstructured":"Ordonez, A. A. et al. Radioiodinated DPA-713 imaging correlates with bactericidal activity of Tuberculosis treatments in mice. Antimicrob. Agents Chemother. 59, 642\u2013649 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"50989_CR14","doi-asserted-by":"publisher","first-page":"e155851","DOI":"10.1172\/JCI155851","volume":"132","author":"CA Ruiz-Bedoya","year":"2022","unstructured":"Ruiz-Bedoya, C. A. et al. High-dose rifampin improves bactericidal activity without increased intracerebral inflammation in animal models of Tuberculous meningitis. J. Clin. Invest. 132, e155851 (2022).","journal-title":"J. Clin. Invest."},{"key":"50989_CR15","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1021\/acsinfecdis.9b00473","volume":"6","author":"F Mota","year":"2020","unstructured":"Mota, F. et al. Radiosynthesis and biodistribution of (18)F-Linezolid in mycobacterium Tuberculosis-infected mice using positron emission tomography. ACS Infect. Dis. 6, 916\u2013921 (2020).","journal-title":"ACS Infect. Dis."},{"key":"50989_CR16","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1021\/acsinfecdis.9b00207","volume":"5","author":"AA Ordonez","year":"2019","unstructured":"Ordonez, A. A. et al. Radiosynthesis and PET bioimaging of (76)Br-Bedaquiline in a murine model of Tuberculosis. ACS Infect. Dis. 5, 1996\u20132002 (2019).","journal-title":"ACS Infect. Dis."},{"key":"50989_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06772-1","volume":"23","author":"T Maitre","year":"2022","unstructured":"Maitre, T. et al. Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial. Trials 23, 928 (2022).","journal-title":"Trials"},{"key":"50989_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.12688\/wellcomeopenres.16783.1","volume":"6","author":"AG Davis","year":"2021","unstructured":"Davis, A. G. et al. Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM]. Wellcome Open Res. 6, 136 (2021).","journal-title":"Wellcome Open Res."},{"key":"50989_CR19","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1056\/NEJMoa040573","volume":"351","author":"GE Thwaites","year":"2004","unstructured":"Thwaites, G. E. et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N. Engl. J. Med. 351, 1741\u20131751 (2004).","journal-title":"N. Engl. J. Med."},{"key":"50989_CR20","doi-asserted-by":"publisher","first-page":"e00021","DOI":"10.1128\/AAC.00021-19","volume":"63","author":"J Xu","year":"2019","unstructured":"Xu, J. et al. Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of Tuberculosis. Antimicrob. Agents Chemother. 63, e00021\u201319 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"50989_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107048","volume":"63","author":"EW Tucker","year":"2024","unstructured":"Tucker, E. W. et al. Linezolid does not improve bactericidal activity of rifampin-containing first-line regimens in animal models of TB meningitis. Int J. Antimicrob. Agents 63, 107048 (2024).","journal-title":"Int J. Antimicrob. Agents"},{"key":"50989_CR22","unstructured":"WHO. Global tuberculosis report 2023. (Geneva: World Health Organization, 2023)."},{"key":"50989_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12941-015-0107-z","volume":"14","author":"S Senbayrak","year":"2015","unstructured":"Senbayrak, S. et al. Antituberculosis drug resistance patterns in adults with tuberculous meningitis: results of haydarpasa-iv study. Ann. Clin. Microbiol. Antimicrob. 14, 47 (2015).","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"50989_CR24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/cid\/ciw763","volume":"64","author":"C Vinnard","year":"2017","unstructured":"Vinnard, C. et al. Long-term mortality of patients with Tuberculous meningitis in New York city: A cohort study. Clin. Infect. Dis. 64, 401\u2013407 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"50989_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/cid\/cix230","volume":"65","author":"AD Heemskerk","year":"2017","unstructured":"Heemskerk, A. D. et al. Clinical outcomes of patients with drug-resistant Tuberculous meningitis treated with an intensified antituberculosis regimen. Clin. Infect. Dis. 65, 20\u201328 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"50989_CR26","doi-asserted-by":"publisher","first-page":"e0270201","DOI":"10.1371\/journal.pone.0270201","volume":"17","author":"EE Evans","year":"2022","unstructured":"Evans, E. E. et al. Long term outcomes of patients with tuberculous meningitis: The impact of drug resistance. PLoS ONE 17, e0270201 (2022).","journal-title":"PLoS ONE"},{"key":"50989_CR27","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1128\/AAC.01354-09","volume":"54","author":"AH Diacon","year":"2010","unstructured":"Diacon, A. H. et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob. Agents Chemother. 54, 3402\u20133407 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"50989_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1128\/AAC.00849-10","volume":"55","author":"Z Ahmad","year":"2011","unstructured":"Ahmad, Z. et al. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob. Agents Chemother. 55, 239\u2013245 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"50989_CR29","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1128\/AAC.00106-09","volume":"53","author":"AM Ginsberg","year":"2009","unstructured":"Ginsberg, A. M., Laurenzi, M. W., Rouse, D. J., Whitney, K. D. & Spigelman, M. K. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob. Agents Chemother. 53, 3720\u20133725 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"50989_CR30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/jnnp.53.1.81","volume":"53","author":"P Phuapradit","year":"1990","unstructured":"Phuapradit, P., Supmonchai, K., Kaojarern, S. & Mokkhavesa, C. The blood\/cerebrospinal fluid partitioning of pyrazinamide: a study during the course of treatment of tuberculous meningitis. J. Neurol. Neurosurg. Psychiatry 53, 81\u201382 (1990).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"50989_CR31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.tube.2010.07.002","volume":"90","author":"PR Donald","year":"2010","unstructured":"Donald, P. R. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis 90, 279\u2013292 (2010).","journal-title":"Tuberculosis"},{"key":"50989_CR32","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/pharmaceutics16010144","volume":"16","author":"S Dong","year":"2024","unstructured":"Dong, S. et al. Drug exposure and susceptibility of pyrazinamide correlate with treatment response in pyrazinamide-susceptible patients with multidrug-resistant tuberculosis. Pharmaceutics 16, 144 (2024).","journal-title":"Pharmaceutics"},{"key":"50989_CR33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/cpt.646","volume":"103","author":"ME Torok","year":"2018","unstructured":"Torok, M. E. et al. Suboptimal exposure to Anti-TB drugs in a TBM\/HIV+ population is not related to antiretroviral therapy. Clin. Pharm. Ther. 103, 449\u2013457 (2018).","journal-title":"Clin. Pharm. Ther."},{"key":"50989_CR34","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/00006454-199203000-00004","volume":"11","author":"RF Jacobs","year":"1992","unstructured":"Jacobs, R. F., Sunakorn, P., Chotpitayasunonah, T., Pope, S. & Kelleher, K. Intensive short course chemotherapy for tuberculous meningitis. Pediatr. Infect. Dis. J. 11, 194\u2013198 (1992).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"50989_CR35","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1021\/jm901858n","volume":"53","author":"L Liu","year":"2010","unstructured":"Liu, L. et al. Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons. J. Med. Chem. 53, 2882\u20132891 (2010).","journal-title":"J. Med. Chem."},{"key":"50989_CR36","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1086\/605576","volume":"49","author":"JW Alffenaar","year":"2009","unstructured":"Alffenaar, J. W. et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin. Infect. Dis. 49, 1080\u20131082 (2009).","journal-title":"Clin. Infect. Dis."},{"key":"50989_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1048653","volume":"13","author":"NF Maranchick","year":"2022","unstructured":"Maranchick, N. F. et al. Cerebrospinal fluid concentrations of fluoroquinolones and carbapenems in tuberculosis meningitis. Front Pharm. 13, 1048653 (2022).","journal-title":"Front Pharm."},{"key":"50989_CR38","unstructured":"Eristavi, M., et al. SimpliciTB Results and Hepatic Safety of Pretomanid Regimens +\/- Pyrazinamide. in CROI 109 (Seattle, Washington, 2023)."},{"key":"50989_CR39","doi-asserted-by":"crossref","unstructured":"Mehta, K., Balazki, P., van der Graaf, P. H., Guo, T. & van Hasselt, J. G. C. Predictions of bedaquiline central nervous system exposure in patients with tuberculosis meningitis using physiologically based pharmacokinetic modeling. Clin. Pharmacokinet. 63, 657\u2013668 (2024).","DOI":"10.1007\/s40262-024-01363-6"},{"key":"50989_CR40","unstructured":"Heinrich, N., et al. PanACEA SUDOCU combination dose-finding trial shows sutezolid is a safe oxazolidinone. in CROI 114 (Seattle, Washington, 2023)."},{"key":"50989_CR41","doi-asserted-by":"publisher","first-page":"e0133869","DOI":"10.1371\/journal.pone.0133869","volume":"10","author":"MG Whitfield","year":"2015","unstructured":"Whitfield, M. G. et al. A global perspective on pyrazinamide resistance: systematic review and meta-analysis. PLoS ONE 10, e0133869 (2015).","journal-title":"PLoS ONE"},{"key":"50989_CR42","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa1507062","volume":"374","author":"AD Heemskerk","year":"2016","unstructured":"Heemskerk, A. D., Bang, N. D. & Thwaites, G. E. Therapy for tuberculous meningitis. N. Engl. J. Med. 374, 2188\u20132189 (2016).","journal-title":"N. Engl. J. Med."},{"key":"50989_CR43","doi-asserted-by":"publisher","first-page":"e85307","DOI":"10.7554\/eLife.85307","volume":"12","author":"E Ardiansyah","year":"2023","unstructured":"Ardiansyah, E. et al. Tryptophan metabolism determines outcome in tuberculous meningitis: a targeted metabolomic analysis. Elife 12, e85307 (2023).","journal-title":"Elife"},{"key":"50989_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.resuscitation.2022.02.024","volume":"174","author":"L Wihersaari","year":"2022","unstructured":"Wihersaari, L. et al. Neurofilament light compared to neuron-specific enolase as a predictor of unfavourable outcome after out-of-hospital cardiac arrest. Resuscitation 174, 1\u20138 (2022).","journal-title":"Resuscitation"},{"key":"50989_CR45","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/cid\/cix540","volume":"65","author":"UK Rohlwink","year":"2017","unstructured":"Rohlwink, U. K. et al. Biomarkers of cerebral injury and inflammation in pediatric tuberculous meningitis. Clin. Infect. Dis. 65, 1298\u20131307 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"50989_CR46","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00658-22","volume":"66","author":"Y Ding","year":"2022","unstructured":"Ding, Y. et al. Superior efficacy of a TBI-166, bedaquiline, and pyrazinamide combination regimen in a murine model of tuberculosis. Antimicrob. Agents Chemother. 66, e0065822 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"50989_CR47","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00035-23","volume":"67","author":"SY Li","year":"2023","unstructured":"Li, S. Y. et al. Next-generation diarylquinolines improve sterilizing activity of regimens with pretomanid and the novel oxazolidinone TBI-223 in a mouse tuberculosis model. Antimicrob. Agents Chemother. 67, e0003523 (2023).","journal-title":"Antimicrob. Agents Chemother."},{"key":"50989_CR48","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1517\/17425255.2013.786042","volume":"9","author":"G Lappin","year":"2013","unstructured":"Lappin, G., Noveck, R. & Burt, T. Microdosing and drug development: past, present and future. Expert Opin. Drug Metab. Toxicol. 9, 817\u2013834 (2013).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"50989_CR49","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41573-020-0080-x","volume":"19","author":"T Burt","year":"2020","unstructured":"Burt, T. et al. Phase 0\/microdosing approaches: time for mainstream application in drug development? Nat. Rev. Drug Discov. 19, 801\u2013818 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"50989_CR50","unstructured":"FDA. Guidance for Industry and Researchers: The Radioactive Drug Research Committee: Human Research Without An Investigational New Drug Application. (2010)."},{"key":"50989_CR51","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2967\/jnumed.117.207431","volume":"59","author":"CA Foss","year":"2018","unstructured":"Foss, C. A. et al. Biodistribution and radiation dosimetry of (124)I-DPA-713, a PET radiotracer for macrophage-associated inflammation. J. Nucl. Med. 59, 1751\u20131756 (2018).","journal-title":"J. Nucl. Med."},{"key":"50989_CR52","doi-asserted-by":"publisher","first-page":"6284","DOI":"10.1128\/AAC.01644-12","volume":"56","author":"EA Weinstein","year":"2012","unstructured":"Weinstein, E. A. et al. Noninvasive determination of 2-[18F]-fluoroisonicotinic acid hydrazide pharmacokinetics by positron emission tomography in Mycobacterium tuberculosis-infected mice. Antimicrob. Agents Chemother. 56, 6284\u20136290 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"50989_CR53","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau0965","volume":"10","author":"EW Tucker","year":"2018","unstructured":"Tucker, E. W. et al. Noninvasive (11)C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis. Sci. Transl. Med. 10, eaau0965 (2018).","journal-title":"Sci. Transl. Med."},{"key":"50989_CR54","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1128\/AAC.05293-11","volume":"55","author":"R Tasneen","year":"2011","unstructured":"Tasneen, R. et al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob. Agents Chemother. 55, 5485\u20135492 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"50989_CR55","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s40262-023-01217-7","volume":"62","author":"K Mehta","year":"2023","unstructured":"Mehta, K., Guo, T., van der Graaf, P. H. & van Hasselt, J. G. C. Predictions of bedaquiline and pretomanid target attainment in lung lesions of tuberculosis patients using translational minimal physiologically based pharmacokinetic modeling. Clin. Pharmacokinet. 62, 519\u2013532 (2023).","journal-title":"Clin. Pharmacokinet."},{"key":"50989_CR56","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/074823379701300401","volume":"13","author":"RP Brown","year":"1997","unstructured":"Brown, R. P., Delp, M. D., Lindstedt, S. L., Rhomberg, L. R. & Beliles, R. P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13, 407\u2013484 (1997).","journal-title":"Toxicol. Ind. Health"},{"key":"50989_CR57","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1111\/bcp.15102","volume":"88","author":"AK Tietjen","year":"2022","unstructured":"Tietjen, A. K., Kroemer, N., Cattaneo, D., Baldelli, S. & Wicha, S. G. Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients. Br. J. Clin. Pharm. 88, 1835\u20131844 (2022).","journal-title":"Br. J. Clin. Pharm."},{"key":"50989_CR58","doi-asserted-by":"publisher","first-page":"e105222","DOI":"10.1371\/journal.pone.0105222","volume":"9","author":"SB Lakshminarayana","year":"2014","unstructured":"Lakshminarayana, S. B. et al. Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis. PLoS ONE 9, e105222 (2014).","journal-title":"PLoS ONE"},{"key":"50989_CR59","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1128\/AAC.01691-15","volume":"60","author":"R Tasneen","year":"2016","unstructured":"Tasneen, R. et al. Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis. Antimicrob. Agents Chemother. 60, 270\u2013277 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"50989_CR60","doi-asserted-by":"publisher","first-page":"e94462","DOI":"10.1371\/journal.pone.0094462","volume":"9","author":"RS Wallis","year":"2014","unstructured":"Wallis, R. S. et al. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS ONE 9, e94462 (2014).","journal-title":"PLoS ONE"},{"key":"50989_CR61","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1128\/AAC.01182-08","volume":"53","author":"KN Williams","year":"2009","unstructured":"Williams, K. N. et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob. Agents Chemother. 53, 1314\u20131319 (2009).","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50989-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50989-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50989-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T13:20:42Z","timestamp":1732627242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50989-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["50989"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-50989-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4096014\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"assertion":[{"value":"16 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Vijay D.\u00a0Ivaturi is a co-founder and Vijay D.\u00a0Ivaturi and Bhavatharini Arun are employees of Pumas-AI, which commercializes Pumas and Lyv software. All other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6657"}}